Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation EuroPCR 2023

Low Dose Direct Oral Anticoagulation vs. DAPT after LAAO - ADALA Trial

Presenter: Xavier Freixa

May 17, 2023

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Conference News EuroPCR 2019

Amplatzer Amulet LAA Closure Device Reduces Stroke Through 2 Years: Global Registry

Caitlin E. Cox

May 31, 2019

News Conference News EuroPCR 2019

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Michael O'Riordan

May 29, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

CHOICE: Better Hemodynamics, Less Structural Deterioration with CoreValve

News Conference News EuroPCR 2019

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Michael O'Riordan

May 24, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

News Conference News EuroPCR 2016

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

Yael L. Maxwell

May 18, 2016

News Conference News EuroPCR 2016

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

Michael O'Riordan

May 17, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

Advertisement

Low Dose Direct Oral Anticoagulation vs. DAPT after LAAO - ADALA Trial

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Amplatzer Amulet LAA Closure Device Reduces Stroke Through 2 Years: Global Registry

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

New Clarity on Patients at High Risk for Bleeding After PCI

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Benefit of LAA Closure Becomes Most Evident After 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content